Booster Therapeutics to develop proteasome activator medicines
Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator medicines…
All articles by Vishnu Priyan
Vishnu Priyan
-
-
KeyBioscience and Eli Lilly extend partnership for obesity treatments
Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing on the development of…
-
Merck unveils $318m biosafety testing facility in Maryland, US
Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, US. The…
-
Arda Therapeutics secures $43m to develop cell depletion therapies
Arda Therapeutics has secured $43m in Series A financing to develop targeted cell depletion therapies. Andreessen Horowitz (a16z Bio +…
-
Boehringer and Circle Pharma link to develop new cancer treatment
Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new precision cancer…
-
FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Zealand Pharma, declining the approval…
-
City Therapeutics launches with $135m Series A funding
City Therapeutics has announced its launch, accompanied by a $135m Series A financing to lead advancements in RNA interference (RNAi)-based…
-
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Ipsen has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for its Elafibranor (Iqirvo) for the treatment…
-
Bayer and MOMA Therapeutics partner for oncology programme
Bayer has entered a strategic collaboration with MOMA Therapeutics to advance a small molecule oncology programme, leveraging the latter’s KNOMATIC…
-
ViiV Healthcare to increase annual supply of long-acting HIV PrEP
ViiV Healthcare has announced plans to triple its annual supply of long-acting cabotegravir for HIV pre-exposure prophylaxis (PrEP) to at…